The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF: Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation. The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations. After termination of extracorporeal circulation, DDAVP (0.3 jig/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes. The increase in factor VIII coagulant activity after infusion did not differ between the groups but there was a significantly larger increase in vWF: Ag levels in DDAVP-treated patients. The aggregatory response to adenosine-diphosphate (ADP) and ristocetin showed a normal pattern and was not significantly different between the two groups. As compared with placebo, DDAVP did not decrease the bleeding time or the postoperative blood loss. We conclude that DDAVP causes an increase in vWFF:Ag levels but does not alter platelet aggregation, bleeding time, or blood loss in uncomplicated coronary artery bypass patients. (Circulation 1990;81:872-878) Acommon problem in cardiac surgery is increased bleeding tendency after cardiopulmonary bypass. The hemostatic defect can be caused by several factors such as a decrease in plasma coagulation factors, increased fibrinolytic activity, inadequate reversal of heparinization, or reduced platelet count as well as defects in platelet function.1,2
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Methods In a prospective double-blind study on 100 patients decided for elective aortocoronary bypass surgery (J.O. Solem, unpublished), randomization to treatment with DDAVP or placebo was made in five blocks of 20 patients each. In each block, there was an equal distribution of DDAVP and placebo. All 20 patients representing one such block (the second) were included in the present investigation. The treatment code was not broken until all five blocks were completed and all laboratory investigations had been performed and evaluated.
Inclusion Criteria
Patients scheduled for at least three vein or internal mammary arterial bypass grafts were selected. All patients gave informed consent to participating. Bleeding time and blood loss. Bleeding time was measured by a modified Ivy technique using a Simplate-II device (General Diagnostics, Morris Plains, New Jersey). Blood loss was measured as the output from the chest drains during the first 10 hours postoperatively and as the total output.
VHII: C and vWF:Ag. VIII: C was measured amidolytically using the chromogenic substrate S-2222 and performed according to the manufacturer (Kabi Vitrum, Stockholm, Sweden). vWF: Ag was measured by an immunoradiometric assay (IRMA) using monoclonal antibodies prepared according to Lamme et a118 and by electroimmunoassay with polyclonal antibodies (EIA), performed according to Holmberg and Nilsson.19 The reference plasma for these determinations was citrated plasma pooled from 20 healthy subjects, the pool having been assayed against the 13th British Standard for factor VIII. The values are expressed as international units (IU) per milliliter.
Platelet Aggregation Study
Platelet-rich plasma (PRP) was prepared by centrifugation at 150g for 10 minutes and platelet-poor plasma (PPP) by centrifugation at 1,OOOg for 10 minutes. PRP and PPP were collected in capped tubes. Platelets were counted through a light microscope. Because of the low platelet count in some of the samples, standardization of platelet numbers with PPP was not performed. Aliquots (0.45 ml) of PRP were incubated at 370 C for 5-10 minutes and, then, stirred with a magnetic bar for 1 minute before adding ADP (Sigma Chemical Co., St. Louis, Missouri) (final concentrations, 0.3, 1, 3, 10, and 30 ,uM) or ristocetin (Sigma Chemical Co.) (final concentrations, 0.5, 0.75, 1.0, and 1.5 mg/ml). Aggregation was performed in a Chrono-Log model 540 aggrometer (Havertown, Pennsylvania) with a Hitachi recorder (Tokyo, Japan). Throughout the study, the maximum slope (Vma,,) of the aggregation curve was measured.
Statistics
As appropriate, data are described with the median±quartile deviation when analyzed by the Wilcoxon rank-sum test and by mean-+±SD when by -0.01+0.33 IU/mi, and this change after infusion was significantly different between the groups (p<0.02). There were no significant differences in these parameters when the EIA was used but the results point in the same direction (Table 4) .
Platelet Aggregation
The aggregatory response to ADP was concentration dependent and tended to be greater in the DDAVP group although the difference between the groups was not significant (Figure 1 ). For each concentration of ADP, the Vmax showed a positive linear correlation to the platelet count in PRP (p<0.05). A normal appearance of second-phase aggregation in response to the higher concentrations of ADP was seen in PRP from all subjects.
Ristocetin-induced aggregation was greater in the DDAVP-treated group but not statistically different from the response in the placebo group for any concentration of ristocetin (Figure 2) . For ristocetin at the higher concentrations (1.0 and 1.5 mg/ml), there tended to be a positive correlation between Vma, and the platelet count in PRP (Figure 3 In the present study, there was an increase in vWF: Ag in most patients after DDAVP administration as compared with the levels measured immedi- Mohr et a12 reported abnormal ristocetin-induced aggregation with delayed, incomplete, or absent response after extracorporeal circulation in 20 patients and attributed these findings to a temporary platelet-membrane defect on the vWF-binding site level. In the present study, we found a normal sensitivity and response to ristocetin in all patients, as compared with the results by Ruggeri et al13 and Holmberg et a124 in normal subjects (threshold levels, 0.72-1.10 and 1.0-1.2 mg/ml, respectively). There was a tendency, however, toward a greater response in the DDAVP-treated patients although not statistically significant. The apparent lack of difference could be a statistical error of the second kind because of the small number of patients, or it might reflect that a normal response to ristocetin is not enhanced by an increase of the vWF:Ag level within the normal range.
ADP increases binding of vWF to platelet membrane glycoprotein complex IIb/IIIa,25 however, ADP-induced aggregation is not considered to be mediated through interaction with vWF. The method was used here to estimate the general platelet activity. The rate of aggregation was dependent on the platelet number in PRP, which was often relatively low and showed a large interindividual variability. With this taken into consideration, the results were normal both qualitatively and quantitatively in both groups but, once again, with a slightly greater (p=NS) response in the DDAVP-treated patients. Our results, however, hardly suggest any clinically important difference in platelet sensitivity between the groups.
We found no difference in the postoperative bleeding time or in blood loss between the two groups. A preliminary analysis of data from the main study in which our patients were included confirms these findings (J.O. Solem, unpublished). Rocha et a120 presented a double-blind prospective trial on DDAVP versus placebo in 100 patients undergoing surgery for valvular heart disease or atrial septal defects, with results agreeing with ours except for a significantly shorter bleeding time and a lower intraoperative blood loss in the DDAVP group. The total blood loss, however, was similar in both groups.20 In our study, intraoperative blood loss was not measured because, in this kind of uncomplicated coronary surgery, the wound is normally closed before the maximum effect of DDAVP can be expected. Hence, the intraoperative blood loss would instead be a measure of the surgical hemostasis, on which DDAVP has no effect.
In contrast to our findings, Salzman et a116 and Czer et al17 found reduced blood loss in DDAVPtreated patients. The patient groups in these studies, however, were different from ours. Thus, Czer et al17 selected only patients with excessive postoperative mediastinal bleeding and used historical controls. Salzman et al16 excluded all uncomplicated coronary artery bypass patients, and had longer duration of extracorporeal circulation and, apparently, more extensive blood loss during operation. Although we must conclude that in uncomplicated coronary artery bypass patients, the vWF:Ag increase caused by DDAVP was not accompanied by enhanced platelet aggregation or reduced bleeding, it cannot be excluded that DDAVP can be beneficial in patients with greater alterations in the hemostatic system.
